Hyperbaric oxygenation for patients with orthostatic dysregulation (postural orthostatic tachycardia) in Long- COVID. Prospectively randomized cross- over study.

Division of Thoracic and Hyperbaric Surgery, Medical University Graz0 个研究点目标入组 40 人开始时间: 2023年2月6日最近更新: 2024年3月12日

适应症

试验速览

暂无简介。

•1.Age 18 -90 years
•2.Evident COVID-19 infection based on clinical diagnosis and at least one positive PCR test or Antibody test
•3.Patients beyond 12 weeks after initial COVID-19 diagnosis, having failed to reassume their former life because of at least two lingering symptoms such as fatigue, dizziness, muscle weakness, insomnia, joint pain, myalgia, or headache lasting at least for 12 weeks (corresponding to grade 2- 4 of the current post-COVID-19 functional status scale)
•4. Patients wit orthostatic dysregulation (postural orthostatic tachycardia) in Long- COVID
•5.No active COVID-19 disease (as documented by negative PCR-test prior to enrolment).
•6.Subject willing and able to read, understand and sign an informed consent and to do self-reporting according to questionnaire.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 35
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•1.Active malignancy
•2.HBOT for any reason prior to study enrolment
•3.Chest pathology incompatible with pressure changes (including untreated pneumothorax, bullous emphysema, moderate to severe asthma)
•4.Ear or sinus pathology incompatible with pressure changes
•5.Pregnancy or breast feeding
•6.Patients unable to give informed consent

发起方

Division of Thoracic and Hyperbaric Surgery, Medical University Graz